Phase 3 N=260 Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Recurrent Vulvovaginal Candidiasis
Primary: Clinical Success — 85; 69; 45; 61 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,030 Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Prostatic Neoplasms
Primary: Overall Survival (OS) — 19.6; 19.0 Months — p=0.1677
Phase 3 N=902 Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Glabellar Lines · Lateral Canthal Lines
Primary: Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown — 769 Participants
Phase 3 N=501 A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML)
Primary: Event Free Survival (EFS) — 5.98; 5.88 Months
Phase 4 N=71 The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain
Nephrolithiasis
Primary: Global Quality of Life Score on Postoperative Day 1 — 4.4; 5.4 score on a scale
Phase 3 N=57 Evaluation of Preoperative N1539 in Colorectal Surgery
Pain, Postoperative
Primary: Evaluation of Safety and Tolerability - Number of Subjects With an AE — 23; 26 participants
Phase 3 N=24 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
Beta-Thalassemia
Primary: Percentage of Participants Who Meet the Definition of Transfusion Independence (TI) — 91.3 Percentage of participants
N/A N=30 Transnasal Induction of Normothermia in Febrile Stroke Patients
Stroke, Ischemic · Stroke Hemorrhagic · Fever
Primary: Cooling Performance — 19 Participants
Phase 4 N=353 Chronic Pain Risk Associated With Menstrual Period Pain
Cystitis, Interstitial · Dysmenorrhea · Migraine Disorders
Primary: Change in Participant Bladder Pain Sensitivity From Baseline. — 38.2; 37.0; 41.2; 47.9 score on a scale — p=.02
Phase 3 N=300 Treatment of Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown at One Month. — 165; 0…
N/A N=35 Modifying Physical Activity and Sedentary Time in Filipino Faith Leaders
Physical Activity and Sedentary Behavior · Healthy Aging
Primary: Minutes Per Week of Hi/Light Intensity Physical Activity — 445; 335; 626; 493 minutes per week — p=<0.05
Phase 3 N=621 Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Geographic Atrophy
Primary: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — 1.7344; 1.7563; 1.9640 mm^2 — p=0.0615
Phase 3 N=380 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Agitation · Schizophrenia · Schizo Affective Disorder
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — 17.5; 17.6; 17.6; -8.4 score on a scale — p=<0.0001
N/A N=36 Clinical Assessment of Two Daily Wear Reusable Soft Silicone Hydrogel Contact Lenses
Refractive Errors
Primary: Distance VA (logMAR) With Study Lenses — -0.08; -0.10; -0.07; -0.07 logMAR
Phase 2 N=32 Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants